RT Journal Article
SR Electronic
A1 Papajik, Tomas
A1 Prochazka, Vit
A1 Raida, Ludek
A1 Kubova, Zuzana
A1 Myslivecek, Miroslav
A1 Drymlova, Jaroslava
A1 Buriankova, Eva
A1 Kucerova, Ladislava
A1 Indrak, Karel
T1 Relapsed follicular lymphoma sequentially treated with rituximab and <sup>90</sup>Y-ibritumomab tiuxetan. Case report
JF Biomedical papers
YR 2007
VO 151
IS 1
SP 109
OP 112
DO 10.5507/bp.2007.020
UL https://biomed.papers.upol.cz/artkey/bio-200701-0020.php
AB Background: Monoclonal antibodies have dramatically changed the treatment possibilities for follicular lymphoma. <sup>90</sup>Y-ibritumomab tiuxetan (Zevalin®) is the first radioimmunotherapy agent approved for the treatment of relapsed and resistant follicular lymphoma patients. Long-term benefit was observed especially for patients achieving CR after radioimmunotherapy.
Methods and Results: A 65-year-old female patient with the second relapse of CD20 positive follicular lymphoma and multiple concomitant diseases was treated with four weekly doses of rituximab (375 mg/m<sup>2</sup>). <sup>18</sup>F-fl uoro-deoxyglucose positron emission tomography combined with computed tomography (PET-CT) demonstrated only partial response to therapy with persistent PET scan positivity in enlarged abdominal lymph nodes. Therefore, it was decided to treat her with a 1200-MBq (32-mCi) dose of <sup>90</sup>Y-ibritumomab tiuxetan radioimmunotherapy. No acute complications were noted afterwards. Hematological nadirs were reached 4 weeks later, with a platelet count of 24x10<sup>9</sup>/l that normalized within the next 2 weeks. The patient had neither infection nor bleeding complications. Eight weeks after radioimmunotherapy, the PET-CT scans documented only 3 lymph nodes around the abdominal aorta, maximum size 2x1 cm. The PET scan analysis proved no accumulation of <sup>18</sup>F-fluoro-deoxy-glucose in any lymph nodes or other organs and tissues.
Conclusions: Sequential treatment with rituximab and <sup>90</sup>Y-ibritumomab tiuxetan may be an interesting alternative in cases of relapsed follicular or other indolent lymphomas in pretreated or older patients with other concomitant diseases.